In this episode, FDA approves Rolvedon to reduce infection incidence; women want more education on sexual health during treatment; abemaciclib regimen shows further signs of benefit and more. Read the full coverage here: FDA approves Rolvedon to reduce infection incidence when taking certain anticancer drugs Women with breast cancer want more education on sexual health during treatment Abemaciclib regimen shows further signs of benefit in advanced breast cancer subgroup Cancer-related fatigue may impact balance after breast cancer treatment Chronic inflammation linked to cognitive difficulties among older breast cancer survivors References: Carroll JE, et al. J Clin Oncol. 2022;doi:10.1200/JCO.22.00406. Goetz MP, et al. Abstract LBA15. Presented at: European Society for Medical Oncology Congress. Sept. 9-13, 2022; Paris. Huynh V, et al. Ann Surg Oncol. 2022;doi:10.1245/s10434-022-12126-7. Press Release Wechsler S, et al. Rehab Oncol. 2022;doi:10.1097/01.REO.0000000000000308.

Ver todos los episodios